Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
February 25, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a...
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
February 13, 2025 10:28 ET
|
Medicenna Therapeutics Corp.
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1...
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
December 13, 2024 08:30 ET
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
Medicenna Provides Clinical Update and Announces First Complete Response in MDNA11 in Combination with KEYTRUDA® (pembrolizumab) Dose Escalation Arm of the ABILITY-1 Study
December 05, 2024 07:35 ET
|
Medicenna Therapeutics Corp.
70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...
Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
November 27, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
November 25, 2024 07:30 ET
|
Medicenna Therapeutics Corp.
MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing...
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
November 15, 2024 07:30 ET
|
Medicenna Therapeutics Corp.
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
November 13, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC
November 11, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with...